Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive

CUMBERLAND PHARMACEUTICALS INC

2024-Q2 EPS reported -$0.21 revenue$18,346,550

Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.
Adjusted earnings $0.2M ($0.01/share), a $0.8M improvement vs prior Q1 period.
Net loss $1.1M ($0.08/share) in Q2; year-to-date net loss $3.0M ($0.21/share).
Product revenue: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M in Q2.
Cash $17.3M; $16.1M drawn on credit line; total assets $78.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.